Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Biodexa Pharmaceuticals

    MCap

    USD3m

    Last close

    USD5.11

    ▲ 1.61 (46.00%)

    Pharnext

    MCap

    EUR1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    KEFI Gold and Copper

    MCap

    GBP36m

    Last close

    GBP0.01

    ▲ 0.15 (25.86%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

Newron Pharmaceuticals (SIX: NWRN)

Currency in CHF

Last close As at 06/12/2023

CHF4.65

▲ 0.09 (1.97%)

Market capitalisation

CHF83m

Newron Pharmaceuticals is focused on the central nervous system. Xadago for Parkinson’s disease (PD) is sold in Europe, Japan, the United States and other regions. Evenamide, a novel schizophrenia add-on therapy, is involved in a Phase II/III trial programme targeting schizophrenia.

Xadago is marketed as an add-on to levodopa therapy in PD. It is currently sold in Europe, Japan, the United States and other territories. Generic manufacturers have notified the FDA of their intention to file generic Xadago products. Newron is contesting these filings. Xadago is currently patent protected until at least 2027.

Latest Insights

View More

Healthcare | Update

Newron Pharmaceuticals — Positive readout highlights evenamide potential

Healthcare | Update

Newron Pharmaceuticals — Crucial upcoming datasets for evenamide

Healthcare | Flash note

Newron Pharmaceuticals — Encouraging efficacy data from evenamide trial

Healthcare | Flash note

Newron Pharmaceuticals — Positive top-line data to support clinical progress
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Arron Aatkar

Associate analyst

Key Management

  • Marco Caremi

    Executive VP of Business Development

  • Stefan Weber

    CEO

Balance Sheet

Forecast net cash (€m)

21.8

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (8.1) (15.5) 244.4
Relative (11.7) (16.0) 247.8
52 week high/low CHF8.0/CHF1.3

Financials

Newron is developing evenamide as an add-on therapy for poorly managed and treatment-resistant schizophrenia (TRS). A potentially pivotal Phase III trial (study 008A) in patients with schizophrenia who are taking antipsychotics but not classified as having TRS is underway; readouts are expected in Q423 or Q124. In the Phase II trial (study 014/015) for patients with TRS, evenamide has demonstrated both safety and efficacy in readouts to date. In October 2023, encouraging interim readouts were reported corresponding to the six-month timepoint for the full 161-patient cohort in extension study 015; full one-year data are expected in Q124. Newron intends to begin an additional, potentially pivotal, multinational Phase III study (study 003) in TRS patients (expected to start in Q124). In its H123 results, Newron recorded total revenue of €5.5m for the period, nearly double H122’s revenue of €2.8m, primarily driven by higher royalty income for Xadago.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2021A 5.8 (11.4) (14.1) (79.23) N/A N/A
2022A 6.1 (12.6) (17.0) (95.34) N/A N/A
2023E 8.9 (11.7) (14.6) (81.90) N/A N/A
2024E 6.8 (19.1) (22.3) (124.77) N/A N/A

Research

Update

Healthcare

Newron Pharmaceuticals — Crucial upcoming datasets for evenamide

Flash note

Healthcare

Newron Pharmaceuticals — Encouraging efficacy data from evenamide trial

Healthcare

Update

Newron Pharmaceuticals — Positive readout highlights evenamide potential
View All

Further insights

insight

Healthcare

Newron Pharmaceuticals: EKF 2023 QuickView

insight

Healthcare

Deutsches Eigenkapitalforum (EKF) 2022 healthcare

insight

Consumer

Deutsches Eigenkapitalforum (EKF) 2022

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

sromanoff@edisongroup.com 020 3077 5700
Read latest

Thematics

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare
volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways

thematic

Healthcare

Machine learning in drug development
View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free